This site is for Healthcare Professionals only | Consumer Site
Visit for additional allergy management information and products.

RHINOCORT® Allergy Spray is generally well tolerated

  • Generally well tolerated in adults and children 6 years of age and older1

Adverse reactions in clinical trials occurring at an incidence of 2% and more commonly than placebo in the RHINOCORT® group in patients 6 years and older*

RHINOCORT® vs. placebo Comparison Chart RHINOCORT® vs. placebo Comparison Chart

A similar adverse event profile was observed in the subgroup of pediatric patients 6-12 years of age. These patients are included in the table. Two to three percent (2%-3%) of patients in the clinical trials discontinued because of adverse reactions.

* Based on 7 controlled clinical studies (N=1526) in adults and children ≥ 6 years old with SAR or PAR treated with RHINOCORT® Allergy Spray at doses up to 400 mcg once daily for 3-6 weeks.

Discontinuation rate

2%-3% of patients in clinical trials discontinued due to adverse reactions


  1. Meltzer EO. Clinical and antiinflammatory effects of intranasal budesonide aqueous pump spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 1998;81(2):128-134.

See data for use in specific populations: pregnancy

Must be signed in to view.